In collaboration with researchers at the University of Florida, Pulmokine is developing novel ACE2 activators as a treatment for PAH. Increasing ACE2 activity with proof of concept small molecule activators has been shown to improve PAH in animals models of the disease. The ACE2 project is in the early lead identification and optimization stage.
In addition, Pulmokine is developing a novel class of kinase inhibitors with in silico modeling and in vitro screening. Through our “in-house” medicinal chemistry expertise we are developing small molecule inhibitors for new targets.